New Science Technology Accelerates Patient Recruitment and Enrollment

New science technology accelerates patient recruitment and enrollment

RESEARCH TRIANGLE PARK, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq: SNCE) today announced new patient relationship management and contact center technology to improve patient engagement, leading to faster patient recruitment and greater enrollment conversion rates.

Science 37’s new patient relationship management platform enables significant efficiency in media planning, placement, reporting and patient communications to yield faster, more qualified patient recruitment for clinical trials. The platform also is able to curate content which can be utilized to improve engagement amongst Science 37’s existing patient community.

After expressing interest in a study, Science 37’s new contact center technology enables near, real-time dialog, across a variety of communications channels, between a qualified patient and a remote study coordinator to ensure that qualified patients who would like to participate have every opportunity to enroll.

“Our new investments in patient relationship management and contact center technology enables us to significantly improve the speed and cost to recruit patients, in addition to our conversion rates from contact to consent,” said Darcy Forman, Chief Delivery Officer, Science 37. “Ultimately, we’re delivering on our mission to provide universal access to anyone, anywhere.”

Enrolling patients in clinical research is the primary driver for clinical trial delays which represent a staggering 80% of all trials¹. This is hardly surprising, given that far fewer than 8% of patients have the opportunity to participate in clinical trials² under the traditional site-based model that poses fundamental access challenges through its intrinsic creation of geographic boundaries.

“While study sponsors often deploy multi-channel approaches to drive patients from outside an investigator’s practice into brick-and-mortar sites, traditional sites have a poor track record in enrolling these referrals into the study because the site’s lack the focus and processes to be successful,” continued Ms. Forman. “The Science 37 enrollment model is fully designed with the mindset that no patient should be left behind.”

About Science 37
Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 l Operating System (OS) supports today’s more agile clinical research designs with its full-stack, end-to-end technology platform and centralized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, provider communities, and data and devices. Configurable to enable almost any study type, the Science 37 OS enables up to 21x faster enrollment, 28% better retention, and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation, and data harmonization. For more information, visit https://www.science37.com.

Sources
¹ Science 37, Brand Benchmark Survey 2022.
² Unger, J.M., Vaidya, R., Hershman, D.L., Miniasian, L.M., Fleury, M.: “Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, Physician and Patient Barriers to Cancer Clinical Trial Participation”; Journal of the National Cancer Institute, Vol. 111, Issue 3, March 2019.

Source: GlobeNewswire